NR1D1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
=== United States === Acetorphine is a Schedule I controlled substance in the United States. Its DEA Administrative Controlled Substances Control Number is 9319 and the one salt in use, acetorphine hydrochloride, has a freebase conversion ratio of 0.93.
=== Rail-linked Inland Container Depots (ICD) === GDL's rail operations are handled by its subsidiary, Gateway Rail Freight Limited. The ICDs are located at Garhi Harsaru (Gurgaon, Haryana), Sahnewal (Ludhiana, Punjab) and Faridabad, Haryana. In 2010, Blackstone Group had invested ₹300 crores in GatewayRail, and then in 2019 GDL bought back the entire shareholding from Blackstone. Company had announced the fifth rail linked container terminal of its subsidiary, Gateway Rail Freight Limited at Viramgam.
Barcodes – The barcode was invented in 1948. However, NASA developed a type of barcode label that could endure in space environments. Cordless power tools – The first cordless power tool was unveiled by Black & Decker in 1961. These were used by NASA and a number of spinoff products came out of those projects such as portable cordless vacuums. Magnetic resonance imaging (MRI), best known as a device for body scanning. NASA contractor JPL developed digital signal processing, which has applications in medical imaging used by MRIs. However, JPL works like a department of NASA. Microchip – The first hybrid integrated circuit was developed by Texas Instruments in 1958, and then the silicon integrated circuit microchip was invented by Robert Noyce at Fairchild Semiconductor in 1959. The impact of NASA was in creating a massive impetus for development in this area. Quartz clocks – The first quartz clock was invented in 1927. However, in the late 1960s, NASA partnered with a company to make a highly accurate quartz clock. Smoke detectors – NASA's connection to the modern smoke detector is that it developed one with adjustable sensitivity as part of the Skylab project; this development helps with nuisance tripping. Space Pen – An urban legend states that NASA spent a large amount of money to develop a pen that would write in space (the result purportedly being the Fisher Space Pen), while the Soviets used pencils. While NASA did spend funds to create a pen to work in space, the project was cancelled due to public opposition, and U.S.
Sources: en.wikipedia.org
== Future == Further advances in aquasome research require additional investigation of their in vivo drug release and targeting. Applications such as delivery of dithranol for the treatment of psoriasis and oral delivery of bromelain for the treatment of inflammatory diseases such as cancer show promising results in vitro and ex vivo. However, such applications have been unexplored in vivo, limiting their clinical use. Applications using aquasomes as carriers of hemoglobin, vaccines, and insulin have been tested in vivo in small animal models such as rats, mice, and rabbits, but current literature lacks in vivo testing in more advanced animal models, preventing their use as treatments for human conditions. Aquasomes are promising drug delivery mechanisms due to their ability to stabilize and transport a variety of substrates while allowing for controlled drug release. Prior to expanding the clinical applications of aquasomes, the gap existing in current literature will need to be filled by further investigating immune clearance of aquasomes, exploring additional surface modifications such as PEGylation, and expanding in vivo drug testing.
Vectorial synthesis is synthesis of exported proteins by ribosomes in which the ribosome-nascent chain complex is bound directly to the endoplasmic reticulum (ER) and the nascent peptide chain moves through the ER membrane as it emerges from the ribosome.
Clobazam, sold under the brand names Frisium and Onfi, among others, is a long-acting benzodiazepine medication primarily used as an anxiolytic and anticonvulsant. Clobazam is a 1,5-benzodiazepine with unique pharmacological characteristics that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Clobazam is solely approved for use in the United States as a treatment for Lennox–Gastaut syndrome, but the drug is available in other countries as an anti-anxiety agent for the short-term treatment of persistent and debilitating forms of anxiety. It has shown a distinct profile and addictive potential compared to the more common benzodiazepines. Clobazam is the only 1,5‑benzodiazepine that has been marketed for clinical use, making it the sole representative of this structural class of benzodiazepines. The drug has been approved by Health Canada as an add-on therapy for generalized tonic–clonic, myoclonic, and focal impaired awareness seizures. In 2011, Lundbeck markets the drug in the United States as Onfi, an adjunctive therapy for seizures associated with Lennox–Gastaut syndrome in patients who are at least two years old.
Sources: en.wikipedia.org
In the 17th century Guillaume Amontons discovered a regular relationship between the pressure and temperature of a gas at constant volume. Some introductory physics textbooks still define the pressure-temperature relationship as Gay-Lussac's law. Gay-Lussac primarily investigated the relationship between volume and temperature and published it in 1802, but his work did cover some comparison between pressure and temperature. Given the relative technology available to both men, Amontons could only work with air as a gas, whereas Gay-Lussac was able to experiment with multiple types of common gases, such as oxygen, nitrogen, and hydrogen.
=== Regulation === The major physiologic triggers of adrenaline release center upon stresses, such as physical threat, excitement, noise, bright lights, and high or low ambient temperature. All of these stimuli are processed in the central nervous system. Adrenocorticotropic hormone (ACTH) and the sympathetic nervous system stimulate the synthesis of adrenaline precursors by enhancing the activity of tyrosine hydroxylase and dopamine β-hydroxylase, two key enzymes involved in catecholamine synthesis. ACTH also stimulates the adrenal cortex to release cortisol, which increases the expression of PNMT in chromaffin cells, enhancing adrenaline synthesis. This is most often done in response to stress. The sympathetic nervous system, acting via splanchnic nerves to the adrenal medulla, stimulates the release of adrenaline. Acetylcholine released by preganglionic sympathetic fibers of these nerves acts on nicotinic acetylcholine receptors, causing cell depolarization and an influx of calcium through voltage-gated calcium channels. Calcium triggers the exocytosis of chromaffin granules and, thus, the release of adrenaline (and noradrenaline) into the bloodstream. For noradrenaline to be acted upon by PNMT in the cytosol, it must first be shipped out of granules of the chromaffin cells. This may occur via the catecholamine-H+ exchanger VMAT1. VMAT1 is also responsible for transporting newly synthesized adrenaline from the cytosol back into chromaffin granules in preparation for release.
== Biocompatibility == Generally PLGA is considered to be quite biocompatible. Its high biocompatibility results from its composition due to lactic and glycolic acid fermentation from sugars, making them eco-friendly and less reactive in the body. PLGA also degrades into non-toxic and non-reactive products that makes them quite useful for various medical and pharmaceutical applications. The biocompatibility of PLGA has been tested both in vivo and in vitro. The biocompatibility of this polymer is generally determined by the products that it degrades into, as well as the rate of degradation into degradation products. The way that PLGA degrades is by means of an enzyme known as esterase, which forms lactic acid and glycolic acid. These acids then undergo the Krebs Cycle to be degraded as carbon dioxide (CO2) and water (H2O). These byproducts then get removed from the body through cellular respiration and through the digestive process. While the byproducts usually do not accumulate in the body, there are instances where these byproducts (lactic and glycolic acid) can be dangerous to the body when accumulated in high local concentrations. There can also be small pieces of the polymers as the polymer degrades, causing an immune response by macrophages. These adverse effects can be reduced by using lower concentrations of the polymer, so that it gets naturally released throughout the body. Something else to consider regarding PLGA biocompatibility is the location at which the polymer is implanted or placed in the body.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.